Create Medicines raised $122 million to expand its in vivo CAR-T platform, focusing on faster, one-day manufacturing using an mRNA-lipid nanoparticle approach to reprogram T cells, NK cells and myeloid cells inside the body. The financing supports ongoing clinical evaluation and additional assets in both oncology and autoimmune indications. At the same time, other players highlighted the operational bottleneck around cell therapy manufacturing—turning a competitive advantage into an execution risk. Automation and quality systems designed for consistent, scalable production are increasingly tied to clinical timelines. The Create update underscores how capital is flowing to companies building end-to-end infrastructure and clinical datasets, not only to new constructs and targets.